US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.820
- +0.040+2.25%
Close Nov 29 13:00 ET
- 1.800
- -0.020-1.10%
Post 17:01 ET
34.32MMarket Cap-1936P/E (TTM)
1.860High1.750Low37.41KVolume1.790Open1.780Pre Close67.52KTurnover0.32%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.10P/B21.51MFloat Cap0.42052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM6.18%Amplitude0.420Historical Low1.804Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Chemomab Therapeutics Stock Forum
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024.
The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 w...
1 min ago
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Resale of up to 8.1 Mln Adss
No comment yet